Sikking, Peisker, Maatz, Lopez-Anguita, Hazebroek, Henkens, Raafs, Heymans, Stroeks, Hamid, A., Li, Vicenzetto, Caforio, Rocca, B.L., Knackstedt, Paassen, v., Empel, v., Hubner, Verdonschot, & Heymans (2026). Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.. European journal of heart failure.
Sikking, Peisker, Maatz, Lopez-Anguita, Hazebroek, Henkens, et al. Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.. European journal of heart failure. 2026; PMID: 42135937
Sikking, Peisker, Maatz, et al. Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.[J]. European journal of heart failure. 2026.
@article{sikking2026,
author = {Sikking and Peisker and Maatz and Lopez-Anguita and Hazebroek and Henkens and Raafs and Heymans and Stroeks and Abdul Hamid and Li and Vicenzetto and Caforio and Brunner-La Rocca and Knackstedt and van Paassen and van Empel and Hubner and Verdonschot and Heymans},
title = {Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.},
journal = {European journal of heart failure},
year = {2026},
note = {PMID: 42135937},
}
TY - JOUR AU - Sikking AU - Peisker AU - Maatz AU - Lopez-Anguita AU - Hazebroek AU - Henkens AU - Raafs AU - Heymans AU - Stroeks AU - Abdul Hamid AU - Li AU - Vicenzetto AU - Caforio AU - Brunner-La Rocca AU - Knackstedt AU - van Paassen AU - van Empel AU - Hubner AU - Verdonschot AU - Heymans TI - Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy. T2 - European journal of heart failure PY - 2026 AN - PMID:42135937 ER -
A previous trial of intravenous immunoglobulin therapy (IVIg) added to guideline-directed medical therapy (GDMT) in patients with dilated cardiomyopathy (DCM) and cardiac parvovirus-B19 (B19V) persistence showed no improvement of cardiac function at six months follow-up. We investigated whether IVIg confers long-term clinical benefits and analyzed its molecular and cellular effects in cardiac tissue to elucidate the immunomodulatory mechanisms underlying the observed long-term clinical improvement.